|
22.11.2026 22:57:01
|
SI-BONE: 3 Key Takeaways for Long-Term Investors
On its third-quarter 2026 earnings call, held on Nov. 2, 2026, SI-BONE (NASDAQ:SIBN) announced a 15% increase in worldwide revenue to $55.7 million, driven by expanding adoption of its surgical implants. The medical device maker is extending its anatomical fixation products into wider spinal applications, positioning itself to capture a larger share of complex surgeries.
Three things management said stand out.
Management launched iFuse Granite Onyx, a medical device designed to fix spinal fusion failures, following clearance from the Food and Drug Administration (FDA). This product extends the company's addressable market by targeting procedures that suffer from high failure rates.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Aktien in diesem Artikel
| SI-BONE Inc Registered Shs | 21,60 | 0,00% |
|